- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01251263
Prevention of Menstrual Migraines: Effects of Estrogen Add-back During the HFI in Patients Using Continuous Oral Contraceptives. (Estradiol/MAM)
This study will examine the combined effects of a continuous oral contraceptive (OC) regimen with supplemental estradiol therapy on headache severity and occurrence in subjects with documented Menstrually Associated Migraines (MAMs). The subjects enrolling in the study will have cyclic menses either due to spontaneous ovulation or use of cyclic hormonal contraception (pill, patch, or ring). Enrolled subjects will start a continuous OC regimen following two baseline menstrual cycles. If breakthrough bleeding/spotting (BTB/BTS) occurs, the subject will institute a 4-day hormone-free interval (HFI). In an attempt to prevent/lessen the severity of headache during the HFI, subjects will be randomized to oral estradiol or placebo during this period. If no BTB/BTS occurs after 80 days of continuous pills, the subject will institute a 4-day HFI during which they will be randomized into estradiol or placebo groups.
The purpose of this research study is to examine the effects of continuous oral contraceptive pills and oral estradiol on headaches that occur around the time of your period. Many woman take continuous oral contraceptive pills (OC) and when OCs are stopped they may get headaches. This study will examine if taking estradiol around the time of the period will affect the headache, and how it will be affected.
This study is a prospective trial. A subject's participation will last approximately 32 weeks.
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Wendy M White, CCRP
- Phone Number: 254-724-8301
- Email: wewhite@swmail.sw.org
Study Locations
-
-
Texas
-
Temple, Texas, United States, 76508
- Recruiting
- Scott and White Hospital & Clinic
-
Principal Investigator:
- Patricia J Sulak, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Women may be on birth control pill (OC), patch or vaginal ring taken in the traditional 21/7 or 24/4 manner, which means that every month they have a period. If they are taking it continuously (without a period), you must be willing to take your birth control 21/7 for 2 months.
- If you are not on OC's, patch or vaginal ring you must have a period every 21-40 days.
- You must not want to get pregnant for 12 months.
- Women who have headaches around the time of their period.
Exclusion Criteria:
- BMI >38
- If you smoke and are age 35 years old or greater or if you are under 35 years old and smoke over 10 cigarettes a day.
- If you have or had an aura with your headaches. (An aura is a temporary sensation, like bright lights that come before you experience the headache)
- Headaches are not occuring during the time of your period.
- Blood Pressure > 140/90 or you take more than a single antihypertensive medication (excluding diuretics) and are age 40 or greater.
- Contraindications to combination estrogen/progestin hormonal contraceptives.
- Desire to become pregnant in the next 12 months.
- Stroke
- Breast Cancer
- Blood clots in your legs, lung or anywhere else in your body.
- Diabetes Mellitus
- Heart Attack
- Liver Disease
- Systemic Lupus Erythematosus
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Group 1
Cyclic OC users prior to initiating study OC.
Estradiol or placebo given in a certain sequence depending on the randomization.
|
Estradiol 1mg twice daily or placebo starting on the last day of OC and continuing during the HFI (total of 9 doses).
Estradiol 1mg will be taken twice daily starting with the last day of pills and the 4 days of the HFI(total of 9 doses)
|
Other: Group 2
Spontaneous ovulation group prior to initiating study OC.
Estradiol or placebo given in a certain sequence depending on the randomization.
|
Estradiol 1mg twice daily or placebo starting on the last day of OC and continuing during the HFI (total of 9 doses).
Estradiol 1mg will be taken twice daily starting with the last day of pills and the 4 days of the HFI(total of 9 doses)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Primary Outcome Measure
Time Frame: 32 weeks
|
Comparing baseline menstrually associated migraines(MAMs) to headache occurance and severity after the implementation of continuous OC therapy.
|
32 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Secondary Outcome Measure
Time Frame: 32 weeks
|
Compare effect of estradiol versus placebo on MAMs severity and duration.
|
32 weeks
|
Collaborators and Investigators
Investigators
- Principal Investigator: Patricia J Sulak, MD, Scott and White Healthcare
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Uterine Diseases
- Headache Disorders, Primary
- Headache Disorders
- Menstruation Disturbances
- Uterine Hemorrhage
- Hemorrhage
- Migraine Disorders
- Metrorrhagia
- Premenstrual Syndrome
- Physiological Effects of Drugs
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Estrogens
- Contraceptive Agents, Hormonal
- Contraceptive Agents
- Reproductive Control Agents
- Contraceptive Agents, Female
- Estradiol
- Estradiol 17 beta-cypionate
- Estradiol 3-benzoate
- Polyestradiol phosphate
Other Study ID Numbers
- 90304
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Menstrual Migraines
-
Trevena Inc.TerminatedMigrainesUnited Kingdom
-
Taipei Medical University WanFang HospitalCompletedIrregular Menstrual Cycle | Regular Menstrual CycleTaiwan
-
University of MinnesotaCompletedEpilepsy | MigrainesUnited States
-
Necmettin Erbakan UniversityNot yet recruitingMenstrual Cycle
-
Gynuity Health ProjectsRecruiting
-
University of FloridaLallemand Health SolutionsActive, not recruitingMenstrual DiscomfortUnited States
-
Canopy Growth CorporationJames Madison UniversityCompleted
-
SPD Development Company LimitedCompleted
-
Istanbul Medipol University HospitalRecruiting
Clinical Trials on Estradiol or Placebo
-
Kronos Longevity Research InstituteMayo Clinic; Albert Einstein College of Medicine; Yale University; Columbia University and other collaboratorsUnknown
-
University of DelawareNational Heart, Lung, and Blood Institute (NHLBI)RecruitingVasodilation | Perimenopause | EstrogenUnited States
-
Samjin Pharmaceutical Co., Ltd.Completed
-
Hospital Ambroise Paré ParisCompletedLumbar RadiculopathyFrance
-
University of Colorado, DenverNational Heart, Lung, and Blood Institute (NHLBI)CompletedMenopause | AgingUnited States
-
Cedars-Sinai Medical CenterCompletedHypothalamic Amenorrhea | Estrogen Deficiency | Cardiovascular Disease (CVD)United States
-
Massachusetts General HospitalNational Institute on Aging (NIA)CompletedPostmenopausal Symptoms | Memory Loss | Cognitive ChangesUnited States
-
Arthrosi TherapeuticsCompletedHealthy VolunteersAustralia
-
E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.Recruiting
-
HK inno.N CorporationUnknownHealthyKorea, Republic of